|
|
| | Cinpanemab Basic information |
| Product Name: | Cinpanemab | | Synonyms: | Cinpanemab;Research Grade Cinpanemab(DHE22001);Cinpanemab (anti-Alpha-synuclein);BIIB054;Research Grade Cinpanemab | | CAS: | 2094516-02-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Cinpanemab Structure]() |
| | Cinpanemab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Cinpanemab Usage And Synthesis |
| Uses | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2]. | | in vivo | Cinpanemab (30 mg/kg; i.p.) improves PD-like phenotypes in α-syn PFF inoculation mouse models [2]. | Animal Model: | C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain[2] | | Dosage: | 30 mg/kg | | Administration: | Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice | | Result: | Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.
|
| | IC 50 | α-synuclein | | References | [1] Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. DOI:10.1056/NEJMoa2203395
[2] Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813. DOI:10.2174/1871527320666210526160926 |
| | Cinpanemab Preparation Products And Raw materials |
|